DEHYDRATED AMNIOTIC MEMBRANE ALLOGRAFT THERAPY FOR COMPLICATED NON-HEALING WOUNDS: A PROMISING THERAPY WHERE OTHER TREATMENTS HAVE FAILED

Daniel J. Beless MD, FCCWS, FACEP and Belinda Marcus, MD, FACEP, CWS
Hyperbaric Physicians of Georgia

OBJECTIVE

Patients referred to wound centers frequently have complicated wounds and co-morbidities that contribute to poor wound healing. Amniotic allografts have been shown to promote healing for many years.

METHODS

This three patient case series demonstrates the effectiveness of Dehydrated Amniotic Membrane Allograft (DAMA) on chronic, non-healing wounds that have failed other advanced therapies. Two of these patients were women who were pregnant when they lost their right leg to severe osteomyelitis. One was a 43-year-old male with a non-healing, chronic diabetic ulcer. Patient reports the left ulcer appeared in 5/2012 and progressed to a deep infection, requiring hospitalization and surgical debridement as well as IV antibiotics.

RESULTS

All three cases responded positively to DAMA. Patients were able to avoid additional surgery and wounds progressed to healing. Each of these patients had been treated with aggressive advanced wound care interventions to extend their underlying condition allowed, but were trending toward local tissue necrosis. Average number of DAMA units utilized in these challenging patients was three. Patients’ wounds were healed in an average of 12 weeks.

CONCLUSIONS

Amniotic allograft demonstrated remarkable ability to help salvage complicated wounds in compromised hosts when other advanced wound care methodologies have previously been unsuccessful. It should be considered an adjunctive modality for salvage of complicated wounds.

References:

*AMNIOEXCEL is a registered trademark of BioD, LLC made available by Derma Sciences Inc, Princeton, NJ
**Integra® Bilayer Wound Matrix®, Integra Life Sciences, Plainsboro, NJ
*** Apiligraf®, Organogenesis, Canton, MA

Derma Sciences provided an educational grant to support this research. The information may include a use that has not been approved or cleared by the Food and Drug Administration.